Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Yield10 Bioscience, Inc. (YTEN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.8500+0.1500 (+5.56%)
At close: 04:00PM EDT
2.8600 +0.01 (+0.35%)
After hours: 07:45PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.7000
Open2.8400
Bid2.5300 x 800
Ask2.8700 x 900
Day's Range2.7000 - 2.8896
52 Week Range1.9100 - 8.7600
Volume40,246
Avg. Volume73,075
Market Cap14.005M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.4180
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for YTEN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Yield10 Bioscience, Inc.
    Analyst Report: Charles River Laboratories International, Inc.Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
    Rating
    Fair Value
    Economic Moat
    11 days agoMorningstar
View more
  • Zacks

    Metabolix, Inc. (YTEN) Reports Q2 Loss, Misses Revenue Estimates

    Metabolix, Inc. (YTEN) delivered earnings and revenue surprises of -1.45% and 37.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Yield10 Bioscience Announces Second Quarter 2022 Financial Results

    -Winter program targeting more than 1,000 acres through grower contracts -On track to achieve key 2022 goal of identifying herbicide tolerant Camelina lines for seed scale up and commercial development -Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update WOBURN, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financ

  • GlobeNewswire

    Yield10 Bioscience to Announce Second Quarter 2022 Financial Results and Host a Conference Call on Wednesday, August 10, 2022

    WOBURN, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its second quarter 2022 financial results and provide a corporate update on Wednesday, August 10, 2022. Management will host a conference call on Wednesday, August 10, 2022 at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following manag

Advertisement
Advertisement